News: chemokine

Detour Around the Estrogen Receptor

Tuesday, January 25th, 2011

About 75 percent of early-stage breast cancers are fueled by estrogen. These estrogen receptor (ER)-positive tumors typically respond to anti-estrogen therapies like tamoxifen, but about a quarter of patients develop resistance to these therapies and the tumors recur. A multi-institutional team of researchers has now identified a potential new target for treating these tumors. The […]